Companies: 10,795·Total market cap: $144.5T
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUTNASDAQHealthcare● Active
$2.39
$-0.29(-10.82%)
Market Cap$303718463
P/E Ratio
52W High$4.31
52W Low$0.62
Overview

Nautilus Biotechnology, Inc. (NAUT) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · NAUT · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.46naut eps ttm · naut earnings per shareEarnings history
PE Ratio (TTM)naut pe ratio ttm · naut price to earningsPE Ratio deep dive
Revenue (TTM)0.00naut revenue ttm · naut annual revenueFull revenue history
Dividend YieldNo Dividenddoes naut pay dividends · naut dividend yieldDividend history
Shares Outstanding126.3Mnaut shares outstanding · naut floatShares outstanding history
Next EarningsAug 4, 2026Est.naut earnings date · naut next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
nautilus biotechnology, inc. revenue · naut revenue 2025
FY 2025Net Income-$59.0M▲ +16.64% YoY
202320242025
nautilus biotechnology, inc. net income · naut profit 2025
FY 2025EPS$-0.47▲ +16.07% YoY
202320242025
naut eps · nautilus biotechnology, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$57.1MEPS: $-0.46View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis naut a buy · naut analyst rating
Strong Buy
0
Buy
3
Hold
1
Sell
1
Strong Sell
0
12-Month Price Target
$2.50Low
$2.39Current
$2.50Avg Target4.60% upside
$2.50High
naut price target · naut 12 month forecast

Total: 5 · Buy rate: 60.0%

The NAUT analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $2.50, representing +4.60% upside from the current price of $2.39.

Stock Performance

Full History
1D-1.67%
1W-12.64%
1M-12.31%
3M-4.86%
YTD+20.51%
1Y+204.40%
5Y-78.00%

About Nautilus Biotechnology, Inc.

CEOSujal Patel
IPO DateAug 7, 2020
Employees134
CountryUS

Nautilus Biotechnology, Inc. a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Pl…

what is nautilus biotechnology, inc. · naut stock overview · nautilus biotechnology, inc. company profile · who is nautilus biotechnology, inc. ceo · naut NASDAQ · nautilus biotechnology, inc. headquarters · nautilus biotechnology, inc. business segments

About Stock Overview & Key Data

Nautilus Biotechnology, Inc. (NAUT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 7, 2020. As of the latest trading session, NAUT stock price is $2.39, with a market capitalization of $298.6M. The stock has returned +204.40% over the past 12 months and +20.51% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Nautilus Biotechnology, Inc. stock is Buy, with an average 12-month price target of $2.50. In fiscal year 2025, Nautilus Biotechnology, Inc. reported revenue of — and net income of -$59.0M. For detailed data — including Nautilus Biotechnology, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Nautilus Biotechnology, Inc. (NAUT) stock price is $2.39. The stock is traded on NASDAQ under the ticker symbol NAUT. The 52-week range is $0.62 – $4.31.

NAUT stock priceNAUT quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice